Clinical trial enrollment in oncology can be complex, and the challenge becomes even greater in heavily pretreated patient populations.  For individuals with platinum-resistant or platinum-refractory ovarian cancer, trial participation often comes after several prior therapies, disease recurrence and repeated cycles of uncertainty.  Xtalks spoke with Tom Zindrick, President and Chief Executive Officer of Genelux, about […]